# GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

> **NCT01553851** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 20 (actual)

## Conditions studied

- Neoplasms, Oral
- Mouth Neoplasms

## Interventions

- **DRUG:** GSK1120212

## Key facts

- **NCT ID:** NCT01553851
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01553851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01553851, "GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01553851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*